GlycoMimetics, Inc. is on the Cruelty Free Investing use of animals list because they use animals for drug testing and clinical trials.
The company stated in the following report that they conduct pre-clinical trials of their drugs on animals.
“The two abstracts describe the results of a series of experiments that demonstrate the activity of GMI’s lead drug candidate, GMI-1070. The candidate is a rationally designed carbohydrate mimic (or “glycomimetic”) that has been shown to inhibit inflammation in several animal models of disease, including vaso-occlusive crisis of sickle cell disease. ” (Page 1) Read the full document.
GlycoMimetics, Inc. operates as a clinical stage biotechnology company, which focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani in April 2003 and is headquartered in Rockville, MD. [Source: MarketWatch]
Company Website: http://glycomimetics.com